A profitable young company in a major growth industry is a rare find. Let alone a medical firm that continues to draw international attention with its ground-breaking studies. Now covered multiple...
Open Orphan
Open Orphan branches out amid infectious disease gold rush
Malaria has plagued humankind since our very evolution. It infects hundreds of millions of people every year and kills hundreds of thousands. Now, with the Covid-19 pandemic still raging on, the...
Near-term profitability, spin outs, and challenge study contracts put Open Orphan on track for major valuation growth (ORPH)
When a company first starts out, profitability can seem a long way off. But after years of hard work, pharmaceutical services firm Open Orphan (LON: ORPH) is hitting that benchmark in style. And not...
Open Orphan rises as Venn wins major contract renewal with biopharma play
Open Orphan (LSE:ORPH) advanced 3% to 23.7p on Monday morning after revealing a contract renewal expected to deliver “significant revenue” over the next 12 months. The specialist pharma services...
Open Orphan expands human challenge trial capacity with new volunteer recruitment centres
Open Orphan (LSE:ORPH) We may have entered a new year, but momentum at Open Orphan continues to build at pace. On Wednesday, the rapidly-growing pharma services firm and AIM darling announced that...
Open Orphan and hVIVO’s human vaccine trial for Covid-19 begins
The first volunteer has been dosed with a COVID-19 vaccine as part of hVIVO’s phase 1 clinical trial of COVI-VAC. Following on from its announcement in July last year, the CRO, part of Open Orphan...
Open Orphan has a great start to 2021 with key 12-month contract renewal
Open Orphan PLC (LSE: ORPH) has recently extended a contract with a top-three global pharma company. Its Venn Life Services subsidiary, operating out of Breda, Netherlands, will provide chemistry,...
Open Orphan wins vaccine contract extension and announces toxicology study completion
Open Orphan (LSE: ORPH) subsidiary Venn Life Sciences has extended a consulting contract with a global pharma firm to support two vaccine development programmes. Venn’s Breda office in the...
“We are scaling-up rapidly and at minimum expense” – Open Orphan’s Cathal Friel on the pharma services firm’s exciting plans for 2021 and beyond
Human challenge study pioneer and AIM darling Open Orphan (LSE:ORPH) is set for a record-breaking 2021. The joint London and Dublin-listed pharma services firm is now profitable for the first...